MAP2K7 and neoplasm: These data raise the hypothesis that clinical trial testing the associating short course of MEK inhibition with chemoimmunotherapy will improve efficacy of chemoimmunotherapies, especially in cold tumor or in tumor lacking CXCL10 production.